• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.高内皮静脉细胞促进的 T 细胞迁移是耗竭调节性 T 细胞后肿瘤控制所必需的。
Cancer Res. 2012 Nov 1;72(21):5473-82. doi: 10.1158/0008-5472.CAN-12-1912. Epub 2012 Sep 7.
2
Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction.耗竭调节性 T 细胞可促进肝脏内嗜肝戊型肝炎病毒新生并促进肿瘤破坏。
Cancer Immunol Res. 2017 Nov;5(11):1005-1015. doi: 10.1158/2326-6066.CIR-17-0131. Epub 2017 Sep 25.
3
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.肿瘤相关三级淋巴结构中的调节性T细胞抑制抗肿瘤T细胞反应。
Immunity. 2015 Sep 15;43(3):579-90. doi: 10.1016/j.immuni.2015.08.006. Epub 2015 Sep 1.
4
Treg-cell depletion promotes chemokine production and accumulation of CXCR3(+) conventional T cells in intestinal tumors.Treg 细胞耗竭促进趋化因子产生和 CXCR3(+)常规 T 细胞在肠道肿瘤中的积累。
Eur J Immunol. 2015 Jun;45(6):1654-66. doi: 10.1002/eji.201445058. Epub 2015 Apr 14.
5
High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer.高内皮静脉血管中的肿瘤浸润淋巴细胞与人类乳腺癌中的淋巴毒素β产生树突状细胞有关。
J Immunol. 2013 Aug 15;191(4):2001-8. doi: 10.4049/jimmunol.1300872. Epub 2013 Jul 3.
6
Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.嗜碱性粒细胞通过趋化作用和浸润 CD8+T 细胞促进肿瘤排斥。
Cancer Res. 2017 Jan 15;77(2):291-302. doi: 10.1158/0008-5472.CAN-16-0993. Epub 2016 Nov 22.
7
Therapeutic depletion of CCR8 tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.CCR8 肿瘤浸润调节性 T 细胞的治疗性耗竭引发抗肿瘤免疫,并与抗 PD-1 治疗协同作用。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001749.
8
Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.调节性 T 细胞耗竭与 gp96 介导的细胞反应和抗肿瘤活性协同作用。
Cancer Immunol Immunother. 2011 Dec;60(12):1763-74. doi: 10.1007/s00262-011-1076-5. Epub 2011 Jul 26.
9
Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APC mice.调节性 T 细胞控制着内皮细胞趋化因子的产生以及 T 细胞向 APC 小鼠肠道肿瘤的迁移。
Cancer Immunol Immunother. 2018 Jul;67(7):1067-1077. doi: 10.1007/s00262-018-2161-9. Epub 2018 Apr 18.
10
Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.调节性T细胞通过在肿瘤部位抑制CD4辅助性T细胞来阻止CD8 T细胞成熟。
J Immunol. 2007 Oct 15;179(8):4969-78. doi: 10.4049/jimmunol.179.8.4969.

引用本文的文献

1
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy.肿瘤相关血管在T细胞归巢与免疫中的作用:癌症治疗的机遇
Nat Rev Immunol. 2025 Jun 27. doi: 10.1038/s41577-025-01187-w.
2
Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.肿瘤微环境中的血管生成与靶向治疗:从基础到临床实践
Clin Transl Med. 2025 Apr;15(4):e70313. doi: 10.1002/ctm2.70313.
3
Pipelines for lymphocyte homeostasis maintenance during cancer immunotherapy.癌症免疫治疗期间维持淋巴细胞稳态的途径。
Front Immunol. 2025 Mar 24;16:1522417. doi: 10.3389/fimmu.2025.1522417. eCollection 2025.
4
Unveiling the immunomodulatory dance: endothelial cells' function and their role in non-small cell lung cancer.揭示免疫调节之舞:内皮细胞的功能及其在非小细胞肺癌中的作用。
Mol Cancer. 2025 Jan 16;24(1):21. doi: 10.1186/s12943-024-02221-6.
5
Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities.三级淋巴结构与免疫治疗:挑战与机遇。
Methods Mol Biol. 2025;2864:299-312. doi: 10.1007/978-1-0716-4184-2_16.
6
Mouse Models Enable the Functional Investigation of Tertiary Lymphoid Structures in Cancer.小鼠模型可用于研究癌症中的三级淋巴结构的功能。
Methods Mol Biol. 2025;2864:57-76. doi: 10.1007/978-1-0716-4184-2_4.
7
Recent clinical researches and technological development in TIL therapy.TIL 疗法的最新临床研究和技术进展。
Cancer Immunol Immunother. 2024 Sep 12;73(11):232. doi: 10.1007/s00262-024-03793-4.
8
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.疾病中的三级淋巴结构:免疫机制与治疗进展。
Signal Transduct Target Ther. 2024 Aug 28;9(1):225. doi: 10.1038/s41392-024-01947-5.
9
Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer.针对乳腺癌中的细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)。
Eur J Med Res. 2024 Jul 2;29(1):353. doi: 10.1186/s40001-024-01901-9.
10
PNAd-expressing vessels characterize the dermis of CD3+ T-cell-mediated cutaneous diseases.表达 PNAd 的血管是 CD3+ T 细胞介导的皮肤疾病真皮的特征。
Clin Exp Immunol. 2024 Mar 12;216(1):80-88. doi: 10.1093/cei/uxae003.

本文引用的文献

1
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.癌症外显子组分析揭示了癌症免疫编辑的 T 细胞依赖机制。
Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755.
2
Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules.树突状细胞通过高内皮小静脉控制淋巴细胞进入淋巴结。
Nature. 2011 Nov 13;479(7374):542-6. doi: 10.1038/nature10540.
3
Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.人类实体瘤中含有高内皮静脉:与 T 淋巴细胞和 B 淋巴细胞浸润相关,并与乳腺癌的良好预后相关。
Cancer Res. 2011 Sep 1;71(17):5678-87. doi: 10.1158/0008-5472.CAN-11-0431. Epub 2011 Aug 16.
4
CD117⁺ CD3⁻ CD56⁻ OX40Lhigh cells express IL-22 and display an LTi phenotype in human secondary lymphoid tissues.在人类次级淋巴组织中,CD117⁺ CD3⁻ CD56⁻ OX40Lhigh 细胞表达 IL-22 并表现出 LTi 表型。
Eur J Immunol. 2011 Jun;41(6):1563-72. doi: 10.1002/eji.201040915. Epub 2011 May 25.
5
Ectopic expression of MECA-79 as a novel prognostic indicator in gastric cancer.MECA-79 的异位表达作为胃癌的一种新的预后指标。
Cancer Sci. 2011 May;102(5):1088-94. doi: 10.1111/j.1349-7006.2011.01895.x. Epub 2011 Mar 17.
6
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.分析肿瘤浸润常规 T 细胞和调节性 T 细胞的 T 细胞受体库,未发现致癌物诱导肿瘤中发生转化的证据。
Cancer Res. 2011 Feb 1;71(3):736-46. doi: 10.1158/0008-5472.CAN-10-1797. Epub 2010 Dec 13.
7
Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.条件性调节性 T 细胞耗竭释放适应性免疫,防止致癌作用并抑制已建立的肿瘤生长。
Cancer Res. 2010 Oct 15;70(20):7800-9. doi: 10.1158/0008-5472.CAN-10-1681. Epub 2010 Oct 5.
8
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.选择性耗竭 Foxp3+调节性 T 细胞可提高建立的黑色素瘤有效治疗性疫苗的疗效。
Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5.
9
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.活化的T效应细胞对肿瘤的浸润有限,限制了调节性T细胞耗竭对已建立的黑色素瘤的治疗活性。
J Exp Med. 2008 Sep 1;205(9):2125-38. doi: 10.1084/jem.20080099. Epub 2008 Aug 25.
10
Regulatory T cells and tumour immunity - observations in mice and men.调节性T细胞与肿瘤免疫——小鼠和人类研究观察
Immunology. 2008 Feb;123(2):157-63. doi: 10.1111/j.1365-2567.2007.02748.x. Epub 2007 Dec 7.

高内皮静脉细胞促进的 T 细胞迁移是耗竭调节性 T 细胞后肿瘤控制所必需的。

T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.

机构信息

Infection and Immunity, School of Medicine, Henry Wellcome Building, Cardiff University, Cardiff, United Kingdom.

出版信息

Cancer Res. 2012 Nov 1;72(21):5473-82. doi: 10.1158/0008-5472.CAN-12-1912. Epub 2012 Sep 7.

DOI:10.1158/0008-5472.CAN-12-1912
PMID:22962270
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3491872/
Abstract

The evolution of immune blockades in tumors limits successful antitumor immunity, but the mechanisms underlying this process are not fully understood. Depletion of regulatory T cells (Treg), a T-cell subset that dampens excessive inflammatory and autoreactive responses, can allow activation of tumor-specific T cells. However, cancer immunotherapy studies have shown that a persistent failure of activated lymphocytes to infiltrate tumors remains a fundamental problem. In evaluating this issue, we found that despite an increase in T-cell activation and proliferation following Treg depletion, there was no significant association with tumor growth rate. In contrast, there was a highly significant association between low tumor growth rate and the extent of T-cell infiltration. Further analyses revealed a total concordance between low tumor growth rate, high T-cell infiltration, and the presence of high endothelial venules (HEV). HEV are blood vessels normally found in secondary lymphoid tissue where they are specialized for lymphocyte recruitment. Thus, our findings suggest that Treg depletion may promote HEV neogenesis, facilitating increased lymphocyte infiltration and destruction of the tumor tissue. These findings are important as they point to a hitherto unidentified role of Tregs, the manipulation of which may refine strategies for more effective cancer immunotherapy.

摘要

肿瘤中的免疫封锁的进化限制了抗肿瘤免疫的成功,但这一过程的机制尚未完全理解。耗竭调节性 T 细胞(Treg),一种抑制过度炎症和自身反应性反应的 T 细胞亚群,可以允许肿瘤特异性 T 细胞的激活。然而,癌症免疫治疗研究表明,激活的淋巴细胞持续无法浸润肿瘤仍然是一个基本问题。在评估这个问题时,我们发现,尽管 Treg 耗竭后 T 细胞的激活和增殖增加,但与肿瘤生长速度没有显著关联。相比之下,肿瘤生长速度低与 T 细胞浸润程度之间存在高度显著的关联。进一步的分析显示,低肿瘤生长速度、高 T 细胞浸润和高内皮小静脉(HEV)的存在之间存在完全一致性。HEV 是通常在次级淋巴组织中发现的血管,它们专门用于淋巴细胞募集。因此,我们的发现表明,Treg 耗竭可能促进 HEV 新生,促进淋巴细胞浸润和肿瘤组织破坏。这些发现很重要,因为它们指出了 Treg 的一个迄今为止尚未识别的作用,对其的操纵可能会完善更有效的癌症免疫治疗策略。